You are here
Therapeutic Considerations in Advanced Renal Cell Carcinoma: A Continuum of Care (J)
Fri 25 Sept / 14:00 - 16:00 / Hall A5
This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.
D. Heng (Canada)
Daniel Heng talks about treatment choices in advanced renal cell carcinoma, considering prognostic scoring, efficacy and safety in everyday practice.
S. Osanto (Netherlands)
Bernard Escudier presents a case study. Susanne Osanto looks at the process of selecting an RCC therapy, and the differences between pazopanib and sunitinib, noting that patient preference is an important consideration.
E. Calvo (Spain)
Emiliano Calvo, who was part of the RECORD-1 trial, talks about the second-line options for patients with advanced kidney cancer. He reviews data from clinical trials including RECORD-1, RECORD-4 and AXIS.